MK-1775 (AZD1775) - WEE1 Inhibitor. CAS# 955365-80-7 Catalog No.:M60299-2S InChi: InChI=1S/C26H26N4O3/c1-29(2)11-6-12-30-15-20(18-13-16(33-3)9-10-22(18)30)24-23(25(31)28-26(24)32)19-14-27-21-8-5-4-7-17(19)21/h4-5

InChi: InChI=1S/C26H26N4O3/c1-29(2)11-6-12-30-15-20(18-13-16(33-3)9-10-22(18)30)24-23(25(31)28-26(24)32)19-14-27-21-8-5-4-7-17(19)21/h4-5

The inhibition of factor inhibiting hypoxia-inducible factor (FIH) by beta-oxocarboxylic acids

Quizartinib inhibits FLT3 with low nanomolar potency in cellular assays and is highly selective when screened against the majority of the human protein kinome

Smiles: CN([C@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](CC1C=CC=CC=1)C(O)=O)OC)[C@@H](C)CC)C(=O)[C@@H](NC(=O)[C@@H](NC)C(C)C)C(C)C

MK-1775 (AZD1775) - WEE1 Inhibitor. CAS# 955365-80-7 Catalog No.:M60299-2S InChi: InChI=1S/C26H26N4O3/c1-29(2)11-6-12-30-15-20(18-13-16(33-3)9-10-22(18)30)24-23(25(31)28-26(24)32)19-14-27-21-8-5-4-7-17(19)21/h4-5MK 1775 (AZD1775), CAS No. 955365 80 7, is a highly potent, selective and orally bioavailable Wee1 kinase inhibitor with IC50 of 5. 2 nM. It abrogated DNA damaged checkpoints induced by gemcitabine, carboplatin, and cisplatin etc. and enhanced the anti tumor efficacy of these agents selectively in p53 deficient tumor cells. At tolerated doses, MK 1775 treatment leads to xenograft tumor growth inhibition or regression. It inhibits Wee1 in H3K36me3